EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug–drug interactions involving canine cytochrome P‐450, UDP‐glucuronosyltransferase, and P‐glycoprotein

Michael H Court iD, Katrina L Mealey iD, Neal S Burke, Tania Perez Jimenez iD, Zhaohui Zhu, Joseph J Wakshlag iD

Journal of Veterinary Pharmacology and Therapeutics · 2024-01 · 47 (1) · 1-13

DOI: 10.1111/jvp.13403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 19.07.2023. Verfasst von Michael H Court und 5 weiteren Autor:innen. Beteiligte Einrichtung: Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, …. Hauptthemen laut MEDLINE: Cannabidiol, Cannabinoids. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ellevet, Washington State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Phytocannabinoid‐rich hemp extracts containing cannabidiol (CBD) and cannabidiolic acid (CBDA) are increasingly being used to treat various disorders in dogs. The objectives of this study were to obtain preliminary information regarding the in vitro metabolism of these compounds and their capacity to inhibit canine cytochrome P450 (CYP)‐mediated drug metabolism and canine P‐glycoprotein‐mediated transport. Pure CBD and CBDA, and hemp extracts enriched for CBD and for CBDA were evaluated. Substrate depletion assays using pooled dog liver microsomes showed CYP cofactor‐dependent depletion of CBD (but not CBDA) and UDP‐glucuronosytransferase cofactor‐dependent depletion of CBDA (but not CBD) indicating major roles for CYP and UDP‐glucuronosytransferase in the metabolism of these phytocannabinoids, respectively. Further studies using recombinant canine CYPs demonstrated substantial CBD depletion by the major hepatic P450 enzymes CYP1A2 and CYP2C21. These results were confirmed by showing increased CBD depletion by liver microsomes from dogs treated with a known CYP1A2 inducer (β‐naphthoflavone) and with a known CYP2C21 inducer (phenobarbital). Cannabinoid‐drug inhibition experiments showed inhibition (IC 50 = 4.6–8.1 μM) of tramadol metabolism via CYP2B11‐mediated N ‐demethylation (CBD and CBDA) and CYP2D15‐mediated O ‐demethylation (CBDA only) by dog liver microsomes. CBD and CBDA did not inhibit CYP3A12‐mediated midazolam 1′‐hydroxylation (IC 50 > 10 μM). CBD and CBDA were not substrates or competitive inhibitors of canine P‐glycoprotein. Results for cannabinoid‐enriched hemp extracts were identical to those for pure cannabinoids. These in vitro studies indicate the potential for cannabinoid–drug interactions involving certain CYPs (but not P‐glycoprotein). Confirmatory in vivo studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolCannabinoidsDogsAnimalsATP Binding Cassette Transporter, Subfamily B, Member 1GlucuronosyltransferaseCytochrome P-450 Enzyme SystemMicrosomes, LiverDrug InteractionsUridine Diphosphate

Stichwörter der Autor:innen

P-glycoproteincannabidiolcytochrome P450dogdrug interaction

Substanzen

cannabidiolic acidCannabidiolATP Binding Cassette Transporter, Subfamily B, Member 1GlucuronosyltransferaseCannabinoidsCytochrome P-450 Enzyme SystemUridine Diphosphate

Autor:innen und Institutionen

  • Program in Individualized Medicine (PrIMe), Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, Washington, USA.
  • Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.

ORCID-Profile: Michael H Court, Katrina L Mealey, Tania Perez Jimenez, Joseph J Wakshlag

Förderung

  • Ellevet
  • Washington State University

Zitieren

APA

Court, M. H., Mealey, K. L., Burke, N. S., Jimenez, T. P., Zhu, Z., & Wakshlag, J. J. (2024). Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug–drug interactions involving canine cytochrome P‐450, UDP‐glucuronosyltransferase, and P‐glycoprotein. Journal of Veterinary Pharmacology and Therapeutics, 47(1), 1-13. https://doi.org/10.1111/jvp.13403

Vancouver

Court MH, Mealey KL, Burke NS, Jimenez TP, Zhu Z, Wakshlag JJ. Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug–drug interactions involving canine cytochrome P‐450, UDP‐glucuronosyltransferase, and P‐glycoprotein. Journal of Veterinary Pharmacology and Therapeutics. 2024;47(1):1-13. doi:10.1111/jvp.13403

BibTeX
@article{Court2024,
  author = {Court, Michael H and Mealey, Katrina L and Burke, Neal S and Jimenez, Tania Perez and Zhu, Zhaohui and Wakshlag, Joseph J},
  title = {Cannabidiol and cannabidiolic acid: Preliminary in vitro evaluation of metabolism and drug–drug interactions involving canine cytochrome P‐450, UDP‐glucuronosyltransferase, and P‐glycoprotein},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2024},
  volume = {47},
  number = {1},
  pages = {1--13},
  doi = {10.1111/jvp.13403}
}
Kostenlos starten →